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Abstract: Fibromyalgia, characterised by persistent pain, fatigue, sleep disturbance and 
cognitive dysfunction, is a central sensitivity syndrome that also involves abnormality in 
peripheral generators and in the hypothalamic pituitary adrenal axis. Heterogeneity of clinical 
expression of fibromyalgia with a multifactorial aetiology has made the development of 
effective therapeutic strategies challenging. Physiological properties of the neurohormone 
melatonin appear related to the symptom profile exhibited by patients with fibromyalgia and 
thus disturbance of it’s production would be compatible with the pathophysiology. Altered 
levels of melatonin have been observed in patients with fibromyalgia which are associated 
with lower secretion during dark hours and higher secretion during daytime. However, 
inconsistencies of available clinical evidence limit conclusion of a relationship between 
levels of melatonin and symptom profiles in patients with fibromyalgia. Administration of 
melatonin to patients with fibromyalgia has demonstrated suppression of many symptoms 
and an improved quality of life consistent with benefit as a therapy for the management of 
this condition. Further studies with larger samples, however, are required to explore the 
potential role of melatonin in the pathophysiology of fibromyalgia and determine the optimal 
dosing regimen of melatonin for the management of fibromyalgia. 
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1. Introduction 
Fibromyalgia, characterised by persistent pain, fatigue, sleep disturbance and cognitive 
dysfunction (i.e. attentional capacity and memory), is a central sensitivity syndrome [1,2]. 
Central sensitization (CS) with neuronal excitability linked to amplified responses of the 
central nervous system (CNS) to peripheral input has been proposed to underlie the 
pathophysiology of fibromyalgia [2]. Peripheral sensory generators, such as nerve 
pathologies, neuroinflammation, skeletal muscle abnormalities and ischaemia, have been 
reported to contribute to this heightened activity of the CNS [3,4]. Consequently, 
fibromyalgia is dominated by disorder of central pain processing producing heightened 
responses to painful stimuli (hyperalgesia) and painful responses to non-painful stimuli 
(allodynia). Heterogeneity of clinical expression with a multifactorial aetiology has made the 
development of effective therapeutic strategies challenging. The aim of this review is to 
consider the relationship of fibromyalgia and melatonin, with respect to involvement in the 
pathophysiology or as a treatment approach of the condition. MEDLINE database, Web of 
Science and Google Scholar were used to identify relevant studies and publications up to 
August 2019 using the terms ‘melatonin’ and ‘fibromyalgia’. 
2. Fibromyalgia 
Classification of fibromyalgia has been based on the American College of 
Rheumatology (ACR) 1990 criteria of widespread pain (for at least 3 months) in all four 
quadrants of the body and pain in 11 of 18 tender point sites [5]. The assessment of the range 
of symptoms by determination of somatic symptom severity (sleep disturbance, cognitive 
disturbance and fatigue) and widespread pain, avoiding reliance on tender points was 
introduced as a revision of the criteria in 2010, with further revision in 2016 to limit potential 
misclassification and introduce the use of a fibromyalgia symptom scale [6,7]. A worldwide 
prevalence, based on application of ACR 1990 criteria, of 0.4–8% of the population has been 
reported for fibromyalgia, being seven times more common in females than males [8]. The 
occurrence of comorbidities (e.g. chronic fatigue syndrome) exhibiting similar symptoms 
however often complicates the recognition of fibromyalgia [2]. 
Altered neurotransmitter functioning and possible neuroplasticity consistent with an 
enhanced excitation and reduced inhibition within the CNS leading to augmented sensory 
processing has been suggested to contribute to the CS in patients with fibromyalgia [3]. 
Raised levels of glutamine (2-fold), nerve growth factor (4-fold), brain-derived neurotrophic 
factor (BDNF, 2 to 4-fold), substance P (2 to 3-fold) and endogenous opioids (3 to 4-fold) 
compared to healthy subjects are observed in the cerebrospinal fluid (CSF) of people with 
fibromyalgia, consistent with involvement of wind-up phenomenon (a progressive increase in 
response reflective of slow temporal summation) leading to self-maintaining CS [2,9]. 
Further, in pain-related brain regions, including the posterior insula, in addition to the CSF 
elevated glutamate, glutamine and glycine levels which correlate to the levels in pain in 
fibromyalgia have been reported [10,11]. In contrast, lower CSF levels of the main 
metabolites of serotonin, 5-hydroxyindoleacetic acid (5-HIAA), and noradrenaline,  
3-methoxy-4-hydroxyphenylglycol (MHPG), and blood levels of serotonin and L-tryptophan 
in people with fibromyalgia relative to healthy subjects have been reported [2,9]. In addition, 
in response to painful stimuli in patients with fibromyalgia dopamine release into the basal 
ganglia is attenuated [12].  
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Alterations in the hypothalamic pituitary adrenal axis (HPA), autonomic nervous system 
and cardiovascular system enhancing or underlying the symptoms of fibromyalgia have been 
linked to systemic stress-related events [2,3]. The symptoms of fibromyalgia being linked to 
HPA and autonomic systems dysregulation has raised interest in the involvement of 
melatonin and the melatonergic system in the pathophysiology of fibromyalgia. 
The characteristic spectrum of symptoms of fibromyalgia cannot be accounted for by 
any of the factors in isolation, such as central or peripheral sensitization, neuroendocrine 
dysfunction, oxidative stress, immunological factors and genetics, linked with the 
pathophysiology. Treatments of the challenges associated with fibromyalgia, as with many 
chronic pain conditions, require the combination of pharmacological and non-pharmacological 
therapeutic approaches [1,6]. An empiric approach to drug therapies is often involved with a 
focus towards individual symptoms, primarily pain, rather than the condition [1]. A primary 
aim of many of the pharmacological treatments is lowering levels of pronociceptive 
excitatory neurotransmission and/or increasing antinociceptive neurotransmission in the CNS. 
Decreased activity of the descending serotonergic-noradrenergic efferent pathways 
responsible for an aberrant diffuse noxious inhibitory control (DNIC) has been observed in 
people with fibromyalgia [2,3]. Thus, current therapeutic options for fibromyalgia are drugs 
that raise serotonin and noradrenaline levels in the CNS (e.g. tricyclic antidepressants, 
serotonin and noradrenaline reuptake inhibitors) or target voltage-gated calcium channel 
subunits (e.g. gabapentin and pregabalin) [1,6]. 
3. Melatonin 
Melatonin (N-acetyl-5-methoxytryptamine), a neurohormone synthesized from 
tryptophan and serotonin (Figure 1), is produced mainly by the pineal gland then crosses the 
blood-brain barrier diffusing into the CSF [13,14]. With a well-defined secretory rhythm 
linked to the circadian rhythm resulting in high circulating concentrations of at night and 
lower during the day melatonin plays in a role in the regulation of the 24-hour pattern of 
bodily functions. Three G-protein coupled melatonergic receptors subtypes have been 
identified at which melatonin acts as a full agonist [14]. Stimulation of MT1 and MT2 
receptors by melatonin leads to activation of inward rectifying potassium channels (Kir) 
and block of Ca2+ channels resulting in a blunting of cell stimulation due to reduced 
formation of cyclic adenosine monophosphate (cAMP) and a lowered intracellular level of 
Ca2+ ions [14,15]. The MT3 receptor has been identified to be quinone reductase protein type 
2, an antioxidant enzyme which is inhibited by melatonin [14]. Various physiological 
functions are affected by melatonin because of the widespread distribution of the 
melatonergic receptors (for example, in the CNS, immune system, gastrointestinal tract, 
blood vessels) [14]. Additional effects of melatonin may also be evoked due to affinity for 
other receptor types including opioid, gamma-aminobutyric acid (GABA), adrenergic, 
serotonergic, cholinergic and N-methyl-D-aspartate (NMDA) [14]. Melatonin is metabolised 
in the liver to produce 6-hydroxymelatonin which is conjugated with sulphate to generate the 
major melatonin metabolite, 6-sulfatoxymelatonin (6-SMT; Figure 1) [16,17]. 6-SMT is 
excreted in urine and is used as an indirect measurement of melatonin production by the 
pineal gland [16,17]. 
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Figure 1. Biosynthesis of melatonin. Melatonin synthesis begins with the 
conversion of tryptophan to serotonin which is acetylated to form  
N-acetylserotonin. Methylation of N-acetylserotonin leads to the production of  
N-acetyl-methoxytryptamine or melatonin. In the liver, melatonin is metabolised 
to 6-hydroxymelatonin which is conjugated with sulphate to 6-sulfatoxymelatonin 
which is used as an indirect measurement of melatonin production. 
Stimulation by melatonin of the MT1 and MT2 receptors of the suprachiasmatic nucleus 
of the hypothalamus improves sleep quality due to a reduction of sleep onset latency, increase 
in sleep duration, sleep efficiency improvement and regulation of sleep-wake cycle [18]. The 
role of melatonin in the suppression of neuronal stimulation leading to sleep onset could be 
relevant in the development and management of aberration of awake-sleep transition 
evident in fibromyalgia [2,5]. The suppressed neuronal stimulation following activation of 
melatonergic receptors by melatonin has also been associated with antinociceptive 
properties [19]. The wide distribution of MT1 and MT2 receptors in CNS, including regions 
crucial for pain control such as the thalamus, hypothalamus, trigeminal tract and nucleus, and 
dorsal horn of the spinal cord, supports the involvement in nociceptive modulation [19–22]. 
In addition to melatonergic receptors the analgesic actions of melatonin also involve GABA 
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receptors, β-endorphins, opioid µ-receptors and the NO-arginine pathway, which also lead to 
a reduction of the intracellular concentration of cAMP [23]. Melatonin could through action 
on the NO-arginine pathway reduce and eliminate wind-up, a perceived progressive increase 
in pain intensity over time when a given painful stimulus is delivered repeatedly that is 
associated with CS in fibromyalgia [2,24]. 
A delayed secretion of melatonin with change in the circadian rhythm has also been 
associated with features of fatigue [15]. In healthy individuals and people with pain 
conditions a strong negative correlation between melatonin level and fatigue has been 
demonstrated [9,25]. Interestingly, the melatonergic receptor agonist agomelatine, but not 
melatonin, reduced the perception of fatigue in subjects with chronic fatigue syndrome [26]. 
In addition to acting as an agonist at MT1 and MT2 receptors, agomelatine exhibits 
antagonistic properties at serotonin 5-HT2C receptors [27]. The action on 5-HT2C receptors 
by agomelatine leads to an increase in the prefrontal cortex of dopaminergic and 
noradrenergic tone resulting in the reduction of fatigue perception [26,27]. Thus, melatonin 
and related drugs may have a role in the fatigue characteristic of fibromyalgia. Melatonin, 
however, may have limited effect of the perception of fatigue in patients with fibromyalgia 
since relative to agomelatine the affinity for 5-HT2C receptors is low [19]. 
Alteration of melatonin levels have also been suggested to contribute to the development 
of cognitive-behavioural problems such as anxiety and depression [28,29]. Activation of the 
melatonergic system, through MT2 receptors, and the GABAergic system, through GABA 
receptors, are believed to be the targets of melatonin for the effects on anxiety [30,31]. People 
with major depression exhibit lowered levels of melatonin, however when used as a treatment 
melatonin does not reduce the depressive symptoms [32–34].  
4. Fibromyalgia and melatonin 
The chronotropic, analgesic and anxiolytic properties of melatonin have stimulated 
interest from both pathophysiological and potential therapeutic perspectives of it’s role in 
fibromyalgia where there is a limited understanding of the pathophysiology and limitations of 
current management strategies. Low levels of tryptophan and serotonin observed in patients 
with fibromyalgia could be associated with a decrease in melatonin synthesis which may 
result in the characteristic symptoms of fibromyalgia of pain and abnormal sleeping 
patterns [2,5]. The abnormal sleeping patterns in patients with fibromyalgia are characterised 
by less sleep efficiency, higher proportion of non-rapid eye movement sleep and more 
arousals per hour of sleep which could be consistent with an abnormal availability of 
melatonin [18,35]. 
4.1. Melatonin and pathophysiology of fibromyalgia 
Investigation of the levels of melatonin in patients with fibromyalgia have observed 
conflicting outcomes with both abnormal levels of melatonin and levels not different relative 
to health controls being reported (Table 1) [36–42]. The inconsistency of outcomes may be 
associated with all studies having low participant numbers, the heterogeneity of the clinical 
characteristics of fibromyalgia and/or methodological variability between the studies, such as 
sample type (urine, serum, blood), marker used (melatonin or 6-SMT) and lack of 
accommodation for circadian rhythm related melatonin dysregulation. In addition, the 
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diversity of participant profiles, e.g. sex, pre- or post-menopausal females, may affect the 
outcomes of such studies. 
Lower melatonin secretion during dark hours in patients with fibromyalgia compared to 
healthy subjects, which may contribute to worse sleep at night, daytime fatigue and higher 
pain perception, has been reported in 2 studies [36,41]. Wikner and colleagues (1998) 
observed that the secretion of melatonin during hours of darkness (23:00–07:00 hours) was 
31% lower in patients with fibromyalgia relative to matched healthy controls with a 36% 
lower peak serum value [36]. In the patients with fibromyalgia a tendency towards decreased 
urinary excretion of melatonin was reported, however statistical significance was not 
achieved. Pernambuco and colleagues (2015) however reported excretion of the major 
melatonin metabolite 6-SMT from 20:00 to 08:00 hours were substantially lower (36%) in 
the urine of patients with fibromyalgia compared to healthy controls [41]. The urinary levels 
of 6-SMT did not correlate with the presence or severity of symptoms assessed by quality of 
life and sleep questionnaires [41]. Altered functioning of the pineal gland and neuroendocrine 
changes related to stress responses could be associated with a reduced production of 
melatonin in people with fibromyalgia [43]. In contrast, Korszun and colleagues (1999) 
reported a higher nocturnal (23:00–06:50 hours) melatonin level in plasma from females with 
fibromyalgia compared with healthy controls [38]. 
Caumo and colleagues (2019) reported a higher melatonin secretion during daytime 
(06:00–18:00 hours) in patients with fibromyalgia which was associated with larger number 
of tender points, lower pain pressure threshold, depressive symptoms and decreased sleep 
quality [42]. The 24 hours load of 6-SMT as a marker of melatonin secretion however did not 
differ between patients with fibromyalgia or healthy controls. The higher daytime hours load 
of melatonin secretion makes patients prone to higher intensity of symptoms characteristic of 
fibromyalgia thus disruption of melatonin secretion rhythm could play a role in the 
pathophysiology of this condition. Alteration of the rhythmic secretion of melatonin will 
affect regulation of the limbic-HPA and sympathetic-adrenergic-noradrenergic systems, 
processes considered to contribute to the pathophysiology of fibromyalgia, due to the density 
and location of the melatonergic receptors [14,44]. 
Similar levels of melatonin in patients with fibromyalgia and healthy controls have 
been observed in three studies [37,39,40]. Press and colleagues (1998) reported nocturnal 
(22:00–07:00 hours) urine levels of 6-SMT to not be different between the two groups of 
subjects [37]. No difference in the circadian rhythm of the blood melatonin levels over 24 
hours in patients with fibromyalgia and healthy controls was reported by Klerman and 
colleagues (2001) [39]. A study by Senel and colleagues (2013) again reported similar 
melatonin levels in plasma of patients with fibromyalgia and healthy controls, however 
measurement was made at only one time point (08:00 hours) [40]. In the latter two studies the 
melatonin levels did not correlate with time of onset of symptoms and sleep disorder, nor 
with the scores of pain and fatigue [39,40]. 
4.2. Melatonin as a therapy 
A therapeutic role of melatonin in the management of fibromyalgia has been 
investigated in several studies which included open-pilot, double-blind randomized controlled 
trial (RCT) and longitudinal placebo-controlled design (Table 2) [45–50]. In all studies 
administration of melatonin (3–15 mg daily) alone or as an adjuvant to patients with 
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fibromyalgia evoked an improvement in the parameters of pain, sleep quality, fatigue, mood 
and quality of life. 
In an open 4-week pilot study, 19 patients with fibromyalgia who received melatonin 3 
mg daily reported at day 30 significant reduction in tender point count and severity of pain, 
and improvement in patient and physician global assessment, and sleep quality [45]. 
Although assessments of fatigue, depression and anxiety appeared to indicate an 
improvement, statistical significance was not achieved. In a second open pilot study, after 15 
days of melatonin 6 mg daily supplementary to their current treatments patients with 
fibromyalgia exhibited an improved sleep/wake cycle with a significant reduction in pain, 
fatigue and depressive symptoms [46]. Thirty days after the initiation of melatonin all other 
medications were withdrawn with no deterioration in control of symptoms. Patients were 
monitored for up to 15 months receiving melatonin 6 mg daily alone and outcomes were 
supportive of chronic melatonin therapy being beneficial in controlling the symptoms of 
fibromyalgia [46]. 
In longitudinal placebo-controlled studies, melatonin 6–15 mg daily alone improved the 
symptoms related to pain, fatigue and sleep quality in patients with fibromyalgia leading to a 
beneficial outcome on quality of life [49,50]. Melatonin treatment (10 consecutive days) 
improved objective sleep quality (12 and 15 mg daily), as assessed by actigraphy, and 
subjective sleep quality (6–15 mg daily), assessed by the Pittsburgh tool, of patients with 
fibromyalgia [49]. Administration of melatonin decreased sleep latency (9–15 mg daily) and 
total nocturnal activity (15 mg daily), and increased sleep efficiency, actual sleep time and 
assumed sleep. In addition to an improved sleep quality, an increase in antioxidant capacity 
levels in the urine of patients with fibromyalgia was observed following treatment with 
melatonin (9–15 mg daily), with the higher dose increasing serum total antioxidant [49]. 
Oxidative stress, particularly in the mitochondria in the peripheral nerves and reduced 
oxidative capacity have been suggested to participate in the pathophysiology of 
fibromyalgia [51,52]. Thus, the elevated antioxidant capacity observed following melatonin 
treatment may play a role in countering oxidative stress and thereby stabilization of the 
physiology of these patients. Further, Castaño and colleagues (2019) observed a significant 
decrease in pain levels with melatonin at 9, 12 and 15 mg daily and a decrease in anxiety 
state at 12 and 15 mg daily [50]. A decrease in urinary cortisol levels was also observed in 
patients with fibromyalgia administered melatonin at 9, 12 and 15 mg daily, consistent with a 
potential inhibitory effect of melatonin on the secretion of cortisol [50,53]. In patients with 
fibromyalgia elevated evening serum cortisol level and blunted morning serum cortisol level 
contrary to that observed in health controls have been reported [54,55]. Thus, the intake of 
melatonin probably decreased circulating cortisol during the night which would provide 
benefit for the patients with fibromyalgia. 
In double-blind RCT studies, melatonin (5 and 10 mg daily for 8 and 6 weeks, 
respectively) alone and as an adjuvant to fluoxetine (20 mg daily) or amitriptyline (25 mg 
daily) further demonstrated an improvement of the spectrum of symptoms in patients with 
fibromyalgia [47,48]. Hussain and colleagues (2011) assessed the effects of melatonin alone 
or melatonin plus fluoxetine in patients with fibromyalgia using the Fibromyalgia Impact 
Questionnaire (FIQ), which includes parameters for pain, fatigue, sleep, morning stiffness, 
anxiety, depression, and health-related quality of life (HRQOL) [47]. Administration of 
melatonin 5 mg daily alone for 60 days significantly reduced FIQ scores relative to  
pre-treatment scores for pain (27%), fatigue (23.7%) sleep disturbance (31.3%), morning 
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stiffness (23%), anxiety (11.6%), depression (23.3%), and HRQOL (10–16.6%) in patients 
with fibromyalgia [47]. When melatonin 5 mg daily was administered in combination with 
fluoxetine 20 mg daily for 60 days to patients with fibromyalgia FIQ scores relative to  
pre-treatment scores were significantly reduced for pain (30%), fatigue (34.7%) sleep 
disturbance (41.3%), morning stiffness (25%), anxiety (21.6%), depression (42.3%), and 
HRQOL (23–37%). Although with combined therapy a greater outcome for HRQOL, pain 
score, fatigue and rest/sleep score was observed with the higher melatonin dose (5 mg daily) 
plus fluoxetine, a better improvement to morning stiffness and anxiety was obtained with 
melatonin (3 mg daily) plus fluoxetine. Interestingly, the administration of melatonin (5 mg 
daily) alone improved fatigue and sleep quality which was not observed with fluoxetine 
alone. Thus, administration of melatonin, alone or in combination with fluoxetine, was 
effective in the treatment of patients with fibromyalgia. De Zanette and colleagues (2014) 
investigated the effects of melatonin 10 mg daily alone or in combination with amitriptyline 
25 mg on the DNIC, the descending pain-modulating system, on pain parameters, sleep 
quality and FIQ scores, and tender point number in patients with fibromyalgia [48]. 
Melatonin alone or in combination with amitriptyline significantly reduced pain score, FIQ 
score and tender point number, improved pain threshold scores and sleep quality; and 
increased the function of the inhibitory DNIC. The combination of melatonin and 
amitriptyline provided additional improvement of the FIQ and pain threshold than 
melatonin alone, thus the concomitant stimulation of melatonergic receptors could possibly 
enhance the aberrant serotonergic-noradrenergic components of the descending endogenous 
pain-modulating system observed in patients with fibromyalgia [48]. Interestingly, serum 
BDNF levels, which are raised in patients with fibromyalgia and may be involved in CS and 
the reduced descending inhibitory system activity, were lowered following administration of 
melatonin alone or in combination with amitriptyline [48]. 
The benefits of melatonin in patients with fibromyalgia varied with respect to dose  
(3–15 mg per day), delay of onset (10 days–8 weeks) and symptom between different studies 
which may be the result of the heterogeneity of subjects (clinical profile), the low participant 
numbers, length of treatment and design of the study. Further work is required to establish the 
optimal dosing regimen (dose, time and method of administration, duration of treatment, 
symptoms targeted) of melatonin for the management of fibromyalgia. 
4.3. Agomelatine, a melatonergic receptor agonist 
The melatonin analogue agomelatine exhibits both high-affinity human melatonergic 
MT1 and MT2 receptors agonist and a serotonin 5-HT2C receptor antagonist properties [27]. 
In two 12 week open-label uncontrolled studies agomelatine (25–50 mg per day) also 
significantly improved pain, depression and anxiety symptoms in patients with 
fibromyalgia [56,57]. But in contrast to melatonin, an improvement in sleep quality was not 
seen with agomelatine [57]. The stimulation of melatonergic receptors is consistent with 
effectiveness in analgesia and mood treatment of patients with fibromyalgia. The outcomes 
with agomelatine, albeit from uncontrolled studies, suggest the control of the sleep disorder 
by melatonin involves mechanisms additional to melatonergic receptors. 
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Table 1. Studies determining the melatonin secretion and 6-sulfatoxymelatonin excretion levels in patients with fibromyalgia. 
Reference Subjects Biomarker Sample Outcome 
Wikner J et al. 
1998 [36] 
8 females with FM;  
8 female HC 
Melatonin Serum collected 
18:00–08:00. 
Urine collected 
22:00–07:00 
Hours of darkness (23:00–07:00) (1.70±0.17 vs 2.48±0.38 nmol/l; P < 0.05) and 
peak (0.28±0.03 vs 0.44±0.06 nmol/l, P < 0.05) serum melatonin levels 
significantly lower (> 30%) in FM compared to HC. Total serum melatonin 
secretion (18:00–08:00) and urinary excretion of melatonin not different between 
FM and HC. 
Press J et al. 
1998 [37] 
39 females with 
FM; 39 female HC 
6-SMT Urine collected 
22:00–07:00 
6-SMT levels not statistically different between FM and HC (16.7±9.2 vs 
16.0±11.3 g). No association between 6-SMT levels in patients with fibromyalgia 
and disease duration and symptoms 
Korszun A et al. 
1999 [38] 
9 females with FM; 
17 female HC 
Melatonin Plasma collected 
hourly over 24 h 
Nocturnal melatonin (23:00–06:50) higher in FM compared to HC (75.2±7.5 vs 
58.5±4.8 pg/ml, respectively, P < 0.05). No difference in timing of offset, onset or 
peak of melatonin secretion between FM and HC. 
Klerman EB et 
al. 2001 [39] 
10 females with 
FM; 12 female HC 
Melatonin Blood collected 
hourly over 24 h 
No significant difference in circadian rhythm (phase and amplitude) of melatonin 
levels in FM and HC. 
Senel K et al. 
2013 [40] 
25 premenopausal 
females with FM; 
20 premenopausal 
female HC 
Melatonin Plasma collected 
at 08:00 
Melatonin levels of patients with fibromyalgia not different from healthy controls 
(10.9±7.3 vs 11.6±7.0 pg/ml, respectively). 
No correlation between melatonin levels and pain scores, fatigue, sleep disorders 
and duration of the disease. 
Pernambuco et 
al. 2014 [41] 
58 females with 
FM; 39 female HC 
6-SMT Urine collected 
20:00–08:00 
Night (20:00–08:00 hours) load lower in FM compared with HC (8.5 (0.3–24.4) vs 
13.3 (0.5–39.8) ng/ml, respectively, P < 0.05). Differences in levels did not 
correlate with FM symptoms. 
Caumo et al. 
2019 [42] 
18 females with 
FM; 17 female HC 
6-SMT Urine collected 
06:00–12:00, 
12:00–18:00, 
18:00–24:00, 
24:00–06:00. 
No difference in daily load of 6-SMT between FM and HC. Daytime  
(06:00–18:00 hours) load higher in FM (0.27 ng/ml; 41.5% of total 24 hr load) 
compared with HC (0.17 ng/ml; 20.7% of total 24 hr load). Daytime load in FM 
correlated with larger number of tender points, lower pain pressure threshold, 
depressive symptoms and decreased sleep quality. 
Note: FM: fibromyalgia; HC: healthy controls; 6-SMT: 6-sulfatoxymelatonin. 
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Table 2. Clinical studies of melatonin as a treatment of fibromyalgia. 
Reference Dose Study design N Duration Domains assessed Outcomes 
Citera et al. 
2000 [45]  
Melatonin 3 mg Pilot 19 4 weeks Tender points 
Pain intensity 
Sleep quality 
All domains improved 
Acuna-
Castroviejo et 
al. 2006 [46] 
Melatonin 6 mg daily Pilot 4 Up to 60 
weeks 
Pain intensity 
Fatigue 
Sleep-wake cycle 
Improved pain and fatigue,  
Sleep-wake cycle normalized 
Hussain SA et 
al. 2011 [47] 
Melatonin 5 mg daily 
alone; Melatonin 3 mg 
daily plus fluoxetine 20 mg 
daily; Melatonin 5 mg daily 
plus fluoxetine 20 mg daily 
Double-blind 
RCT 
101 8 weeks FIQ score (quality of life, 
pain, fatigue, sleep quality, 
anxiety, depression) 
FIQ score improved with melatonin 
alone or in combination with 
fluoxetine. Combination achieved a 
greater effectiveness.  
De Zanette et 
al. 2014 [48] 
Melatonin 10 mg daily 
alone, 
Amitriptyline 25 mg daily 
alone, 
Melatonin 10 mg daily plus 
amitriptyline 25 mg daily 
Double-blind 
RCT 
63 6 weeks Pain, pain threshold, tender 
points, sleep quality 
Melatonin alone or in combination 
was more effective than amitriptyline 
alone on pain symptoms and 
threshold. 
All 3 treatments were equally 
effective on tender points and sleep 
quality. 
Castaño et al. 
2018 [49] 
Melatonin 3, 6, 9, 12, 15 
mg daily 
Longitudinal 
placebo-
controlled design 
33 10 days Objective sleep assessment 
(actigraphy), subjective 
sleep assessment 
(Pittsburgh test), Total 
antioxidant capacity 
Objective and subjective sleep quality 
was improved by 12 and 15 mg, and 
6–15 mg melatonin respectively. 
Total antioxidant capacity was 
increased by 9–15 mg melatonin.  
Castaño et al. 
2019 [50] 
Melatonin 3, 6, 9, 12, 15 
mg daily 
Longitudinal 
placebo-
controlled design 
36 10 days FIQ score, Pain Score,  
SF-36. State-Trait Anxiety 
Inventory, Mood Scale,  
Pain levels, mood, quality of life, 
anxiety levels and FIQ scores 
improved. 
Note: FIQ: Fibromyalgia impact questionnaire; N: number of participants; RCT: randomized controlled trial; SF-36: Short Form-36 Health Survey. 
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5. Conclusion 
Melatonin is involved in circadian rhythm synchronisation and thereby regulation of the  
sleep-awake cycle and fatigue, and in addition enhances endogenous pain inhibition processes and 
mood. Thus, the physiological processes maintained by the availability of melatonin are relevant to 
the clinical features of fibromyalgia where persistent pain, fatigue, sleep disorder and cognitive 
impairment are characteristic. Lowered levels of serotonin and tryptophan, precursors of melatonin, 
in patients with fibromyalgia have been correlated with many of the symptoms and consequently 
have led to melatonin playing a role in the pathophysiology of this condition being investigated [2,5]. 
An increased nociception may be associated with the reduced production of melatonin observed in 
patients with fibromyalgia which could present clinically as hyperalgesia and/or allodynia [19,36,41]. 
Thus, if a disturbance in melatonin production is associated with the pathophysiology of 
fibromyalgia, the use of melatonin could offer a novel treatment approach. 
Altered levels of melatonin have been observed in patients with fibromyalgia which are 
associated with lower secretion during dark hours and higher secretion during daytime. The changes 
in melatonin levels during dark hours would contribute to sleep disturbance with raised pain 
perception and fatigue during the day. The changes in melatonin levels during daytime would 
exacerbate the symptoms of pain and fatigue, lead to depressive symptoms and enhance disturbance 
of sleep quality. A bidirectional relationship exists between pain and sleep, such that poor sleep is 
linked with next-day pain and daytime pain is associated with reduced night-time sleep [58]. The 
altered circadian rhythm and sleep architecture due to changes in melatonin secretion may amplify 
pain and mask the ability to inhibit pain. Thus, melatonin could be involved in the pathophysiology 
of fibromyalgia with the aberrant secretion consistent with expression of the main symptoms of 
fibromyalgia. Conflicting studies, however, have reported melatonin levels in patients with 
fibromyalgia not different from those observed in healthy subjects. Although the properties of 
melatonin appear consistent with an involvement in the expression of the main symptoms presented 
by patients with fibromyalgia, there does not appear to be a relationship between melatonin levels 
and the profile of symptoms. Studies have used low participant numbers to investigate a condition 
that exhibits heterogeneity of clinical characteristics and methodological inconsistencies that would 
introduce variability of outcomes. 
The chronotropic, analgesic and anxiolytic properties have led to melatonin being investigated 
as a potential therapeutic agent to treat fibromyalgia. Although the number of studies is limited with 
a diversity of trial design, all investigations have demonstrated beneficial outcomes of melatonin as a 
therapy for the management of fibromyalgia with a suppression of many of symptoms and an 
improved quality of life. The outcomes of melatonin administration to patients with fibromyalgia are 
consistent with improvement of the symptoms due to regulation of circadian rhythm synchronisation 
and a direct effect on pain pathways, and/or on the levels of signalling chemicals that regulate pain 
[48-50]. Combination therapy studies with melatonin plus fluoxetine or amitriptyline have provided 
further evidence of efficacy as a treatment of fibromyalgia and support investigation of other 
concomitant medications. The available combination therapy evidence is not sufficient to identify 
preferable treatment options. Further studies with larger samples are required to explore the optimal 
dosing regimen of melatonin for the management of fibromyalgia. 
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